RWE and Clinical Trials To Take Center Stage In UK Sector Deal Prospects
Some of the loudest messages from UK government's Life Science Sector Deal was the importance of using real world evidence - and the uniqueness the British health ecosystem can offer to trail blazing innovation.
You may also be interested in...
The international biopharma industry is backing the UK life sciences sector, with UCB spearheading the charge with a £1bn commitment to R&D in the nation still in a state of flux regarding its exit from the European Union in 2019.
The pharmaceutical industry wants the UK to improve its uptake of innovative medicines in order to spur investment in clinical trials under the government's life sciences sector deal. One industry representative says companies are already questioning the ethics of conducting trials in a country where their drug might not be commercialized.
Successfully piecing together the agreed life sciences sector deal calls for the UK to embrace high-risk innovation and placing the NHS at its center, says Sir John Bell who helped formulate the pact.